| scholarly article | Q13442814 |
| P50 | author | Cheuk Chun Szeto | Q37840506 |
| P2093 | author name string | Wong KC | |
| Wang A | |||
| Lai FM | |||
| Lui SF | |||
| Leung CB | |||
| Li EK | |||
| Tam LS | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lupus nephritis | Q1621830 |
| P304 | page(s) | 573-580 | |
| P577 | publication date | 1998-08-01 | |
| P1433 | published in | QJM: An International Journal of Medicine | Q7265477 |
| P1476 | title | Long-term treatment of lupus nephritis with cyclosporin A. | |
| P478 | volume | 91 |
| Q36407314 | Basic immunosuppressive drugs outside solid organ transplantation |
| Q33882751 | Current status of lupus nephritis |
| Q38372154 | Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study |
| Q58204835 | Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice |
| Q53161789 | Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis. |
| Q42458610 | Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study |
| Q36634248 | Emerging drug therapies for systemic lupus erythematosus |
| Q33915484 | How accelerated atherosclerosis in SLE has changed our management of the disorder |
| Q43031095 | Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. |
| Q40115721 | Low dose cyclosporine A in the treatment of resistant proliferative lupus nephritis. |
| Q26740487 | Lupus Nephritis in Asia: Clinical Features and Management |
| Q22000837 | Lupus nephritis: current update |
| Q37754815 | Management of systemic lupus erythematosus in Chinese patients |
| Q36915693 | New treatment strategies for proliferative lupus nephritis: keep children in mind! |
| Q38542910 | Pharmacokinetic modeling of therapies for systemic lupus erythematosus. |
| Q36054839 | Prognostic factors in lupus nephritis |
| Q58204921 | Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis |
| Q36242892 | Rationale for T cell inhibition by cyclosporin A in major autoimmune diseases |
| Q37678723 | Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. |
| Q28144533 | Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients |
| Q35208185 | Severity of systemic lupus erythematosus with diffuse proliferative glomerulonephritis and the ineffectiveness of standard pulse intravenous cyclophosphamide therapy in Jamaican patients |
| Q34567937 | T lymphocyte activation--an inside overview. |
| Q46407226 | Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. |
| Q38925320 | The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review |
| Q38829637 | The safety of pharmacological treatment options for lupus nephritis |
| Q33818039 | The value of repeat biopsy in lupus nephritis flares |
| Q34074960 | Therapy of systemic lupus erythematosus: new agents and new evidence |
| Q36118534 | Treatment for lupus nephritis: a revisit |
| Q42728756 | Treatment of lupus nephritis |
| Q78814998 | Treatment of lupus nephritis |
| Q35201234 | Treatment of severe proliferative lupus nephritis: the current state |
| Q74022703 | Treatment of systemic lupus erythematosus |
| Q78679215 | [Current therapy of lupus nephritis] |
| Q84600171 | [Immunosuppresive treatment in patients with lupus glomerulonephritis. Review of adverse events] |
Search more.